This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Genetic Testing Drive Invitae's (NVTA) Q2 Earnings?
by Zacks Equity Research
Invitae (NVTA) expects to deliver a strong second quarter, banking on solid performance of its genetic testing business.
Invitae (NVTA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed at $25.76 in the latest trading session, marking a +0.39% move from the prior day.
Bear of the Day: Illumina (ILMN)
by Kevin Cook
The NASA of biotech just hit a growth speed-bump on its way to helping the world explore ancestry and disease
Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed at $24.47 in the latest trading session, marking a -0.04% move from the prior day.
Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed at $22.62 in the latest trading session, marking a -1.74% move from the prior day.
Invitae (NVTA) Catches Eye: Stock Jumps 9.1%
by Zacks Equity Research
Invitae (NVTA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Why These Innovative Biotech ETFs Are Soaring
by Neena Mishra
Strong M&A activity has sent shares of many small, innovative biotech companies surging
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
46 and You: Genetic Testing = Giant Growth Market
by Kevin Cook
Advances in genomic diagnostic technology have made testing affordable for the 99.0% of the world still in line.
Bull of the Day: Illumina (ILMN)
by Kevin Cook
The NASA of biotech is helping the world explore crucial genetic information to understand ancestry and disease
2 Healthcare Innovators To Buy Now
by Kevin Cook
My innovation radar is hot on the trail of genetic diagnostics and advanced medical records IT.
Invitae (NVTA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of -2.17% and -12.85%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Invitae (NVTA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerner (CERN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner (CERN) in Q1. However, expected decline in bookings is likely to be a dampener.
Invitae (NVTA) Scales a New 52-Week High on Solid Prospects
by Zacks Equity Research
One of the key growth drivers for Invitae (NVTA) is an increase in billable tests over the past year.
Invitae (NVTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Invitae (NVTA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.
Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of 4.26% and 8.59%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Invitae (NVTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Sweta Killa
Sector ETF report for ARKG
Implied Volatility Surging for Invitae (NVTA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Zacks Equity Research
Sector ETF report for ARKG
Invitae (NVTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of 16.07% and 21.54%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Cerner (CERN) Looks Good: Stock Adds 6.2% in Session
by Zacks Equity Research
Cerner (CERN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Zacks Equity Research
Sector ETF report for ARKG